Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus OTOBIOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus OTOBIOTIC.
CORTIFOAM vs OTOBIOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Otobiotic is a fixed-dose combination of ciprofloxacin (a fluoroquinolone antibiotic) and fluocinolone acetonide (a corticosteroid). Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial DNA replication inhibition and cell death. Fluocinolone acetonide suppresses inflammation by binding to glucocorticoid receptors, modulating gene expression, and reducing inflammatory mediators.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Adults and children: 3-4 drops into the affected ear twice daily for 7 days. Shake well before use.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life: 2-3 hours in patients with normal renal function; prolonged to 24-48 hours in anuria.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal elimination of unchanged drug: 60-80%; biliary/fecal elimination: 10-20%; the remainder undergoes hepatic metabolism.
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid